MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.50
-0.93
-6.44%
Pre Market: 13.63 +0.13 +0.96% 07:01 09/21 EDT
OPEN
13.87
PREV CLOSE
14.43
HIGH
14.01
LOW
13.29
VOLUME
1.50K
TURNOVER
--
52 WEEK HIGH
34.71
52 WEEK LOW
11.88
MARKET CAP
613.73M
P/E (TTM)
-4.8366
1D
5D
1M
3M
1Y
5Y
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Sept. 17, 2021: NSTG, IRDM, TSLA, LC, CRBU, CLLS
NanoString Technologies (NSTG) - 104,400  Iridium Communications (IRDM) - 167,417 Tesla (TSLA) - 14,362  LendingClub (LC) - 401,984  Caribou Biosciences (CRBU)
Benzinga · 19h ago
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Sept. 10, 2021: IOVA, NSTG, U, NVDA, TRMB, IRDM, TTD, LC, CLLS, CRBU, DRNA, PSTG, PSTI, NVS, SPR
Iovance Biotherapeutics (IOVA) - 132,377  Nanostring Technologies (NSTG) - 55,617  Unity Software (U) - 138,794  Nvidia (NVDA) - 300 Trimble (TRMB) - 15,880  Iridium
Benzinga · 09/13 14:52
European ADRs Move Higher in Wednesday Trading
MT Newswires · 09/01 11:30
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Aug. 30, 2021: IOVA, MCRB, ISRG, BABA, NXPI, GOOG, MELI, SE, PSTI, CLLS
Iovance Biotherapeutics (IOVA) - 71,749 Seres Therapeutics (MCRB) - 846,468 Intuitive Surgical (ISRG) - 1,700 Alibaba Group Golding (BABA) - 15,089 NXP Semiconductors (NXPI)
Benzinga · 08/31 14:57
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Aug. 27, 2021: MCRB, NSTG, IOVA, BABA, LC, OKTA, CLLS, PSTI, BMY
Seres Therapeutics (MCRB) - 1,282,095  NanoString Technologies (NSTG) - 66,400  Iovance Biotherapeutics (IOVA) - 444,050  Alibaba Group (BABA) - 13,593  LendingClub (LC)
Benzinga · 08/30 14:39
Cellectis Announces Participation in Five Investor Conferences
Cellectis S.A. (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, ...
GlobeNewswire · 08/26 20:34
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLLS. Analyze the recent business situations of Cellectis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLLS stock price target is 32.88 with a high estimate of 50.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 126
Institutional Holdings: 17.69M
% Owned: 38.90%
Shares Outstanding: 45.46M
TypeInstitutionsShares
Increased
17
400.78K
New
10
2.34M
Decreased
35
1.63M
Sold Out
11
102.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman
Jean-Pierre Garnier
Chief Executive Officer/Co-Founder/Executive Board/Director
Andre Choulika
Co-Founder/Executive Vice President/Executive Board/Director
David Sourdive
Chief Financial Officer/Executive Board
Eric Dutang
Chief Human Resource Officer/Executive Vice President/Executive Board
Kyung Nam-Wortman
Executive Vice President/Executive Board
Jon Voss
Senior Vice President/Executive Board
Leopold Bertea
Senior Vice President/Executive Board
Steven Doares
Senior Vice President
Mark Frattini
Chief Scientific Officer/Executive Board
Philippe Duchateau
Chief Compliance Officer/Executive Board
Stephan Reynier
General Counsel/Executive Board
Marie-Bleuenn Terrier
Executive Board
Carrie Brownstein
Executive Board
Arthur Stril
Non-Executive Independent Director
Laurent Arthaud
Non-Executive Independent Director
Pierre Bastid
Non-Executive Independent Director
Rainer Boehm
Non-Executive Independent Director
Alain Godard
Non-Executive Independent Director
Herve Hoppenot
Non-Executive Independent Director
Annick Schwebig
No Data
  • All
  • Financials
  • Insiders
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.